Comment on ‘Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines’

TY - JOUR

T1 - Comment on ‘Diagnosis and treatment of basal cell carcinoma

T2 - European consensus-based interdisciplinary guidelines’

AU - European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC)

AU - Peris, Ketty

AU - Fargnoli, Maria C.

AU - Garbe, Claus

AU - Kaufmann, Roland

AU - Bastholt, Lars

AU - Seguin, Nicole B.

AU - Bataille, Veronique

AU - del Marmol, Veronique

AU - Dummer, Reinhard

AU - Harwood, Catherine A.

AU - Hauschild, Axel

AU - Höller, Christoph

AU - Haedersdal, Merete

AU - Malvehy, Josep

AU - Middleton, Mark R.

AU - Morton, Colin A.

AU - Nagore, Eduardo

AU - Stratigos, Alexander J.

AU - Szeimies, Rolf Markus

AU - Tagliaferri, Luca

AU - Trakatelli, Myrto

AU - Zalaudek, Iris

AU - Eggermont, Alexander

AU - Grob, Jean J.

N1 - Funding Information: K.P. reports receiving grants and personal fees from Almirall and Abbvie , during the conduct of the study, and personal fees for Advisory Board Meeting from Biogen, Lilly, Celgene, Galderma, LEO Pharma, Novartis, Pierre Fabre, Sanofi, Sandoz, Sun Pharma and Janssen, outside the submitted work. M.C.F. reports receiving personal fees from Roche and Mylan; grants and personal fees from Galderma , during the conduct of the study; grants and personal fees from Abbvie , Almirall , Leo Pharma , Novartis , Sanofi and UCB and personal fees from Janssen, Lilly, Celgene and Pierre Fabre, outside the submitted work. C.G. reports receiving grants and personal fees from Roche ; personal fees from Sun Pharma, during the conduct of the study; personal fees from Amgen, MSD, Philogen and Sanofi and grants and personal fees from BMS , Novartis , NeraCare , outside the submitted work. R.K. reports receiving personal fees and clinical trial grants from Roche related to aspects of the submitted work, personal fees from Amgen, BMS, Novartis, Regeneron and Actelis, as well as clinical trial grants to his institution from Amgen , BMS , Novartis , Abbvie , Almirall , Biogen , MSD and Pfizer, outside the submitted work. L.B. reports receiving personal fees from Amgen, BMS, Novartis, Merck, Roche, Eisai, Astra Zeneca and Pfizer, outside the submitted work. N.B.-S. reports receiving grants and personal fees from Roche; personal fees from Sun Pharma; non-financial support and other support from PellePharm, during the conduct of the study, and personal fees from Pierre Fabre and LaboratoireLéo, outside the submitted work. V.B. has given a few lectures on cutaneous side-effects of targeted therapy and immunotherapy in stage 3 and 4 melanoma for Novartis and MSD. V.d.M. reports receiving fees from Sanofi, Merck, Abbvie and served as an employee in Hopital Erasme where he received funding from BMS. She also reports receiving research grant from Abbvie and Janssen . R.D. has intermittent, project focused consulting and/or advisory relationships with Novartis, Merck Sharp & Dhome (MSD), Bristol-Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma and Sanofi, outside the submitted work. C.A.H. reports receiving other support from PellePharm, during the conduct of the study; personal fees from Sanofi; non-financial support from MEDA; grants from Leo; other support from Novartis; grants from Almirall and CERIES/Channel and other support from Galderma, outside the submitted work. A.H. reports receiving grants and personal fees from Amgen , BMS , MerckSerono , MSD/Merck , Novartis Pharma, Philogen , Pierre Fabre , Provectus , Regeneron , Roche , Sanofi Genzyme and personal fees from OncoSec, Sun Pharma, outside the submitted work. C.H. reports receiving personal fees from Amgen, BMS, MSD, Novartis, Sanofi, Incyte, Pierre Fabre and Roche, outside the submitted work. M.H. reports receiving non-financial support from CynosureHologic, grants from Leo Pharma , grants and non-financial support from Lutronic and Novoxel , non-financial support from PerfAction Technologies and grants from Procter & Gamble and Sebacia , outside the submitted work. J.M. reports receiving grants and personal fees from Roche ; personal fees from Sun Pharma, during the conduct of the study; personal fees and grants from Amgen , Almirall , BMS and Novartis and personal fees from MSD, outside the submitted work. Dr. Mark M. Middleton reports receiving personal fees from Amgen; grants and personal fees from Roche and GSK; grants from Astrazeneca; personal fees and other support from Novartis; other support from Millenium; personal fees, non-financial support and other support from Immunocore; personal fees and other support from BMS; other support from Vertex; personal fees and other support from Eisai; other support from Pfizer; personal fees, non-financial support and other support from Merck; personal fees and other support from Rigontec; other support from Regeneron and TCBiopharma, personal fees from BioLineRx, personal fees and other support from Array Biopharma and other support from Replimune, outside the submitted work. Dr. Colin Morton reports receiving personal fees from Biofrontera and Galderma, outside the submitted work; Dr Morton served as a board member of Euro-PDT. Dr Morton serves as national PI for a study sponsored by Biofrontera. E.N. reports receiving personal fees from Novartis, outside the submitted work. A.J.S. reports receiving personal fees and/or research support from Novartis, Roche, BMS, Merck, Abbvie, Pfizer, Sanofi, Regeneron and LEOPharma, outside the submitted work. R-.M.S. reports receiving grants, personal fees and non-financial support from Galderma International; grants and non-financial support from Biofrontera ; grants, personal fees and non-financial support from Leo Pharma , during the conduct of the study; grants and personal fees from Almirall ; grants from Dr. Wolff-Group ; grants from Eli Lilly and Company ; grants from Galapagos ; personal fees and non-financial support from Janssen ; grants and personal fees from Novartis and grants from photonamic , outside the submitted work. L.T. reports no conflict of interest. In addition, L.T. has a patent TIMER applicator pending. Dr. Myrto Georgia Trakatelli reports receiving personal fees from Genesis Pharma, Leo Pharma, Janssen Pharma and Novartis, outside the submitted work. I.Z. reports receiving grants and personal fees from Roche Oncology and Mylan, during the conduct of the study; personal fees from Sanofi and Regeneron; grants from Abbvie and personal fees from MSD, Novartis and MedaPharma, outside the submitted work. A.E. reports receiving personal fees, all outside the submitted work, from BMS, Ellipses, GSK, HalioDX, Incyte, IO Biotech, ISA pharmaceuticals, MedImmune, Merck-Serono, MSD, Novartis, Pfizer, Polynoma, Sellas and Sanofi, as well as equity in RiverDiagnostics, SkylineDx and Theranovir. J.J.G. reports receiving personal fees from MSD, BMS, Roche, Novartis, Amgen, Pierre Fabre, Sanofi, Merck Pfizer and Sun Pharma, outside the submitted work. Funding Information: K.P. reports receiving grants and personal fees from Almirall and Abbvie, during the conduct of the study, and personal fees for Advisory Board Meeting from Biogen, Lilly, Celgene, Galderma, LEO Pharma, Novartis, Pierre Fabre, Sanofi, Sandoz, Sun Pharma and Janssen, outside the submitted work. M.C.F. reports receiving personal fees from Roche and Mylan; grants and personal fees from Galderma, during the conduct of the study; grants and personal fees from Abbvie, Almirall, Leo Pharma, Novartis, Sanofi and UCB and personal fees from Janssen, Lilly, Celgene and Pierre Fabre, outside the submitted work. C.G. reports receiving grants and personal fees from Roche; personal fees from Sun Pharma, during the conduct of the study; personal fees from Amgen, MSD, Philogen and Sanofi and grants and personal fees from BMS, Novartis, NeraCare, outside the submitted work. R.K. reports receiving personal fees and clinical trial grants from Roche related to aspects of the submitted work, personal fees from Amgen, BMS, Novartis, Regeneron and Actelis, as well as clinical trial grants to his institution from Amgen, BMS, Novartis, Abbvie, Almirall, Biogen, MSD and Pfizer, outside the submitted work. L.B. reports receiving personal fees from Amgen, BMS, Novartis, Merck, Roche, Eisai, Astra Zeneca and Pfizer, outside the submitted work. N.B.-S. reports receiving grants and personal fees from Roche; personal fees from Sun Pharma; non-financial support and other support from PellePharm, during the conduct of the study, and personal fees from Pierre Fabre and LaboratoireLéo, outside the submitted work. V.B. has given a few lectures on cutaneous side-effects of targeted therapy and immunotherapy in stage 3 and 4 melanoma for Novartis and MSD. V.d.M. reports receiving fees from Sanofi, Merck, Abbvie and served as an employee in Hopital Erasme where he received funding from BMS. She also reports receiving research grant from Abbvie and Janssen. R.D. has intermittent, project focused consulting and/or advisory relationships with Novartis, Merck Sharp = Dhome (MSD), Bristol-Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma and Sanofi, outside the submitted work. C.A.H. reports receiving other support from PellePharm, during the conduct of the study; personal fees from Sanofi; non-financial support from MEDA; grants from Leo; other support from Novartis; grants from Almirall and CERIES/Channel and other support from Galderma, outside the submitted work. A.H. reports receiving grants and personal fees from Amgen, BMS, MerckSerono, MSD/Merck, Novartis Pharma,Philogen, Pierre Fabre, Provectus, Regeneron, Roche, Sanofi Genzyme and personal fees from OncoSec, Sun Pharma, outside the submitted work. C.H. reports receiving personal fees from Amgen, BMS, MSD, Novartis, Sanofi, Incyte, Pierre Fabre and Roche, outside the submitted work. M.H. reports receiving non-financial support from CynosureHologic, grants from Leo Pharma, grants and non-financial support from Lutronic andNovoxel, non-financial support from PerfAction Technologies and grants from Procter = Gamble and Sebacia, outside the submitted work. J.M. reports receiving grants and personal fees from Roche; personal fees from Sun Pharma, during the conduct of the study; personal fees and grants from Amgen, Almirall, BMS and Novartis and personal fees from MSD, outside the submitted work. Dr. Mark M. Middleton reports receiving personal fees from Amgen; grants and personal fees from Roche and GSK; grants from Astrazeneca; personal fees and other support from Novartis; other support from Millenium; personal fees, non-financial support and other support from Immunocore; personal fees and other support from BMS; other support from Vertex; personal fees and other support from Eisai; other support from Pfizer; personal fees, non-financial support and other support from Merck; personal fees and other support from Rigontec; other support from Regeneron and TCBiopharma, personal fees from BioLineRx, personal fees and other support from Array Biopharma and other support from Replimune, outside the submitted work. Dr. Colin Morton reports receiving personal fees from Biofrontera and Galderma, outside the submitted work; Dr Morton served as a board member of Euro-PDT. Dr Morton serves as national PI for a study sponsored by Biofrontera. E.N. reports receiving personal fees from Novartis, outside the submitted work. A.J.S. reports receiving personal fees and/or research support from Novartis, Roche, BMS, Merck, Abbvie, Pfizer, Sanofi, Regeneron and LEOPharma, outside the submitted work. R-.M.S. reports receiving grants, personal fees and non-financial support from Galderma International; grants and non-financial support from Biofrontera; grants, personal fees and non-financial support from Leo Pharma, during the conduct of the study; grants and personal fees from Almirall; grants from Dr. Wolff-Group; grants from Eli Lilly and Company; grants from Galapagos; personal fees and non-financial support from Janssen; grants and personal fees from Novartis and grants from photonamic, outside the submitted work. L.T. reports no conflict of interest. In addition, L.T. has a patent TIMER applicator pending. Dr. Myrto Georgia Trakatelli reports receiving personal fees from Genesis Pharma, Leo Pharma, Janssen Pharma and Novartis, outside the submitted work. I.Z. reports receiving grants and personal fees from Roche Oncology and Mylan, during the conduct of the study; personal fees from Sanofi and Regeneron; grants from Abbvie and personal fees from MSD, Novartis and MedaPharma, outside the submitted work. A.E. reports receiving personal fees, all outside the submitted work, from BMS, Ellipses, GSK, HalioDX, Incyte, IO Biotech, ISA pharmaceuticals, MedImmune, Merck-Serono, MSD, Novartis, Pfizer, Polynoma, Sellas and Sanofi, as well as equity in RiverDiagnostics, SkylineDx and Theranovir. J.J.G. reports receiving personal fees from MSD, BMS, Roche, Novartis, Amgen, Pierre Fabre, Sanofi, Merck Pfizer and Sun Pharma, outside the submitted work.

PY - 2020/5

Y1 - 2020/5

UR - http://www.scopus.com/inward/record.url?scp=85083578783&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2020.02.040

DO - 10.1016/j.ejca.2020.02.040

M3 - Letter

C2 - 32241671

AN - SCOPUS:85083578783

SN - 0959-8049

VL - 131

SP - 100

EP - 103

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -